12 Month Price Forecast For MEDS
Distance to MEDS Price Forecasts
MEDS Price Momentum
🤔 Considering Trxade (MEDS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 7:08 PM UTC
MEDS Analyst Ratings & Price Targets
Currently, there are no Wall Street analyst price targets or forecasts available for MEDS (Trxade).
MEDS is currently trading at $4.50. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MEDS Analyst Consensus
MEDS Price Target Range
Latest MEDS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MEDS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 1, 2023 | EF Hutton | Fozia Ahmed | Buy | Assumes | $1.25 |
| May 16, 2023 | EF Hutton | Constantine Davides | Buy | Maintains | $1.25 |
| Mar 28, 2023 | Maxim Group | Allen Klee | Buy | Maintains | $1.75 |
| Dec 9, 2021 | EF Hutton | Constantine Davides | Buy | Initiates | $4.50 |
| Dec 3, 2020 | National Securities Corporation | Buy | Initiates | $0.00 | |
| Dec 3, 2020 | National Securities | Buy | Initiates | $0.00 |
Stocks Similar to Trxade Group Inc
The following stocks are similar to Trxade based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Trxade Group Inc (MEDS) Financial Data
Trxade Group Inc has a market capitalization of $13.28M with a P/E ratio of -0.2x. The company generates $7.45M in trailing twelve-month revenue with a 56.7% profit margin.
Revenue growth is -94.9% quarter-over-quarter, while maintaining an operating margin of -7,998.8% and return on equity of -3,290.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Trxade Group Inc (MEDS) Company Overview
About Trxade Group Inc
Operates a health services IT platform.
The company generates revenue by providing a web-based platform that connects licensed pharmaceutical wholesalers with government organizations, hospitals, clinics, and independent pharmacies. By facilitating the buying and selling of brand, generic, and non-drug products, it earns fees for transactions conducted on its platform.
Headquartered in Tampa, Florida, TRxADE HEALTH, Inc. serves a diverse range of clients in the healthcare sector, which positions it well to capitalize on the ongoing demand for efficient pharmaceutical distribution solutions.
Company Information
Sector
Healthcare
Industry
Pharmaceutical Retailers
Employees
8
CEO
Mr. Surendra K. Ajjarapu
Country
United States
IPO Year
2019
Website
www.trxadehealth.comTrxade Group Inc (MEDS) Latest News & Analysis
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”
3 months agoTRxADE Health, Inc. has rebranded to Scienture Holdings, Inc. and changed its ticker symbol to SCNX, while continuing to operate as a Nasdaq-listed company.
The rebranding to Scienture Holdings and the new ticker SCNX may signal a strategic shift or new focus, potentially affecting investor perception and stock performance.
TRxADE Health, Inc. will rebrand its subsidiary Scienture, LLC to Scienture Holdings, Inc. on September 23, 2024, with a new ticker symbol NASDAQ:SCNX.
The name change and new ticker symbol for TRxADE's subsidiary may impact investor perception and trading activity, potentially affecting stock liquidity and valuation as it rebrands.
TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team
5 months agoTRxADE Health, Inc. announced the appointment of Narasimhan Mani, Ph.D., MBA as President of its subsidiary Scienture, with Shankar Hariharan remaining as CEO and Rahul Surana promoted to Executive VP and COO.
Leadership changes at TRxADE and Scienture could influence strategic direction and operational efficiency, impacting investor confidence and stock performance.
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
5 months agoScienture, Inc. has merged with TRxADE Health Inc. in an all-stock deal valued at $103 million.
The $103 million all-stock transaction indicates potential growth and market expansion for Scienture, Inc., possibly impacting its stock value and overall industry positioning.
TRxADE Health, Inc. Announces Special Cash Dividend
6 months agoTRxADE Health, Inc. (Nasdaq: MEDS) has declared a special cash dividend of $1.50 per share, payable on July 24, 2024, to stockholders of record as of July 19, 2024.
The declaration of a special cash dividend signals strong cash flow and financial health, potentially boosting shareholder confidence and attracting new investors to TRxADE HEALTH.
TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
7 months agoTRxADE HEALTH, Inc. (Nasdaq: MEDS) received a notice from Nasdaq for failing to file its Quarterly Report for Q1 2024, impacting its compliance with listing requirements.
TRxADE HEALTH's non-compliance with Nasdaq filing requirements raises concerns about its financial health and governance, potentially impacting investor confidence and share price.
Frequently Asked Questions About MEDS Stock
What is Trxade Group Inc's (MEDS) stock forecast for 2025?
Analyst forecasts for Trxade Group Inc (MEDS) are not currently available. The stock is trading at $4.50.
Is MEDS stock a good investment in 2025?
Analyst ratings for MEDS are not currently available. The stock is currently trading at $4.50. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MEDS stock?
Price predictions from Wall Street analysts for MEDS are not currently available. The stock is trading at $4.50.
What is Trxade Group Inc's business model?
The company generates revenue by providing a web-based platform that connects licensed pharmaceutical wholesalers with government organizations, hospitals, clinics, and independent pharmacies. By facilitating the buying and selling of brand, generic, and non-drug products, it earns fees for transactions conducted on its platform.
What is the highest forecasted price for MEDS Trxade Group Inc?
Price targets from Wall Street analysts for MEDS are not currently available. The stock is trading at $4.50.
What is the lowest forecasted price for MEDS Trxade Group Inc?
Price targets from Wall Street analysts for MEDS are not currently available. The stock is trading at $4.50.
What is the overall MEDS consensus from analysts for Trxade Group Inc?
Analyst ratings for MEDS are not currently available. The stock is trading at $4.50.
How accurate are MEDS stock price projections?
Stock price projections, including those for Trxade Group Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
